Furthermore, it has been shown that ABT263 treatment and BCL2 inhibition induces OXPHOS impairment in primary acute myelogenous leukaemia (AML) and normal marrow CD34+ cells [32]. Here, BCL2 is linked to acute myeloid leukemia.